- Home
- FTFT vs KZIA Comparison
FTFT vs KZIA Comparison
Compare FTFT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- KZIA
- Stock Information
- Founded
- FTFT N/A
- KZIA 1994
- Country
- FTFT United States
- KZIA Australia
- Employees
- FTFT N/A
- KZIA N/A
- Industry
- FTFT Business Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- KZIA Health Care
- Exchange
- FTFT Nasdaq
- KZIA Nasdaq
- Market Cap
- FTFT 11.0M
- KZIA 9.0M
- IPO Year
- FTFT N/A
- KZIA 1999
- Fundamental
- Price
- FTFT $2.06
- KZIA $7.04
- Analyst Decision
- FTFT
- KZIA Strong Buy
- Analyst Count
- FTFT 0
- KZIA 3
- Target Price
- FTFT N/A
- KZIA $16.00
- AVG Volume (30 Days)
- FTFT 131.6K
- KZIA 187.3K
- Earning Date
- FTFT 11-18-2025
- KZIA 11-14-2025
- Dividend Yield
- FTFT N/A
- KZIA N/A
- EPS Growth
- FTFT N/A
- KZIA N/A
- EPS
- FTFT N/A
- KZIA N/A
- Revenue
- FTFT $2,368,206.00
- KZIA $1,549,158.00
- Revenue This Year
- FTFT N/A
- KZIA N/A
- Revenue Next Year
- FTFT N/A
- KZIA $49.25
- P/E Ratio
- FTFT N/A
- KZIA N/A
- Revenue Growth
- FTFT N/A
- KZIA 248983.08
- 52 Week Low
- FTFT $1.01
- KZIA $2.86
- 52 Week High
- FTFT $5.70
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- FTFT 45.45
- KZIA 44.03
- Support Level
- FTFT $2.00
- KZIA $6.79
- Resistance Level
- FTFT $2.37
- KZIA $7.29
- Average True Range (ATR)
- FTFT 0.18
- KZIA 0.45
- MACD
- FTFT -0.01
- KZIA 0.03
- Stochastic Oscillator
- FTFT 14.29
- KZIA 42.78
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.